OncoNano Medicine to Present at American Association for Cancer Research Virtual Conference on Immunology and Tumor Immunotherapy

SOUTHLAKE, Texas, September 30, 2021– (BUSINESS WIRE) – OncoNano Medicine, Inc. today announced a poster presentation at the American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy to be held October 5 and 6, 2021.

Full details of the presentation are listed below:

TITLE: ONM-501 – A versatile synthetic agonist of STING for cancer immunotherapy

PRESENTER: Qintai Su, Ph.D.
DATED: October 5-6, 2021
SITE: Virtual

The development of ONM-501 represents a new concept of activation of STING that could overcome the challenges observed with previous STING agonists. ONM-501 encapsulates the endogenous STING agonist cGAMP with a proprietary micelle that induces polyvalent STING condensation and prolongs innate immune activation to provide dual “burst” and “sustained” STING activation for potentially highly effective immunotherapy against STING. Cancer.

About OncoNano Medicine

OncoNano Medicine is developing a new class of products that use the principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to assist patients across the continuum of cancer care and include solid tumor therapies, agents for real-time image-guided surgery, and a therapy platform. immuno-oncology drugs that activate and guide the body’s immune system to target cancer. .

OncoNano’s primary development candidate is pegsitacianin, a novel fluorescent nanoprobe, currently under investigation in phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano’s second development program, is a next-generation STING (STimitator of INterferon genes) agonist that progresses to a first human trial in the first half of 2023. Pegsitacianin and ONM-501 were supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at www.OncoNano.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210930005048/en/

Contacts

MacDougall
Lauren Arnold
781-235-3060
[email protected]


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *